During the last session, Standard BioTools Inc (NASDAQ:LAB)’s traded shares were 5.49 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stock’s price was $1.88, reflecting an intraday gain of 7.43% or $0.13. The 52-week high for the LAB share is $3.04, that puts it down -61.7 from that peak though still a striking 35.64% gain since the share price plummeted to a 52-week low of $1.21. The company’s market capitalization is $697.77M, and the average intraday trading volume over the past 10 days was 2.04 million shares, and the average trade volume was 2.08 million shares over the past three months.
Standard BioTools Inc (LAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. LAB has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Standard BioTools Inc (NASDAQ:LAB) trade information
Standard BioTools Inc (LAB) registered a 7.43% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.43% in intraday trading to $1.88, hitting a weekly high. The stock’s 5-day price performance is 5.62%, and it has moved by 1.08% in 30 days. Based on these gigs, the overall price performance for the year is -2.59%. The short interest in Standard BioTools Inc (NASDAQ:LAB) is 21.33 million shares and it means that shorts have 16.02 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.25, which implies an increase of 42.15% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.25 and $3.25 respectively. As a result, LAB is trading at a discount of -72.87% off the target high and -72.87% off the low.
Standard BioTools Inc (LAB) estimates and forecasts
Statistics show that Standard BioTools Inc has outperformed its competitors in share price, compared to the industry in which it operates. Standard BioTools Inc (LAB) shares have gone down -25.98% during the last six months, with a year-to-date growth rate more than the industry average at 26.83% against 24.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 66.70% this quarter and then jump 72.00% in the quarter after that. In the rating firms’ projections, revenue will increase 61.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 41M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 47.03M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 25.37M and 28.19M respectively. In this case, analysts expect current quarter sales to grow by 61.60% and then jump by 66.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.72%. While earnings are projected to return 56.74% in 2024, the next five years will return -8.06% per annum.
LAB Dividends
Standard BioTools Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Standard BioTools Inc insiders own 1.95% of total outstanding shares while institutional holders control 72.14%, with the float percentage being 73.58%. CASDIN CAPITAL, LLC is the largest shareholder of the company, while 185.0 institutions own stock in it. As of 2024-06-30, the company held over 63.96 million shares (or 17.1782% of all shares), a total value of $113.21 million in shares.
The next largest institutional holding, with 58.65 million shares, is of VIKING GLOBAL INVESTORS LP’s that is approximately 15.7524% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $103.81 million.
